MedTrace Logo

Impact of CRRT on Serum Carnitine and Micronutrient Levels

NCT07467889 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2026-03-16

No results posted yet for this study

Summary

This study aims to investigate the changes in blood levels of micronutrients and carnitine in critically ill patients with Acute Kidney Injury (AKI) who are undergoing Continuous Renal Replacement Therapy (CRRT). While CRRT is a life-saving intervention for managing metabolic disturbances and fluid overload in patients with Stage 2-3 AKI, it may also lead to the inadvertent removal of essential micronutrients (vitamins, trace elements, and amino acids) through the extracorporeal circuit.

The research will prospectively compare 100 adult patients across two groups: those receiving CRRT and those managed without CRRT. Researchers will analyze blood samples and effluent fluid to determine the clearance rates and total losses of various substances, including carnitine, selenium, zinc, and various amino acids. By comparing levels at the first hour and 24th hour of intensive care admission, the study seeks to determine if CRRT significantly contributes to micronutrient deficiencies in this vulnerable population.

Conditions

  • Acute Kidney Injury (Nontraumatic)
  • Critical Illness

Interventions

PROCEDURE

Continuous Renal Replacement Therapy (CRRT)

atients receive CRRT in Continuous Veno-venous Hemodialysis (CVVHD) mode with a target dose of 30 mL/kg/hour. The procedure uses a polysulfone Ultraflux AV1000S filter with a surface area of 1.8 m2. Anticoagulation is provided with unfractionated heparin. Blood flow rate (Qb) is set between 100-140 mL/min, and dialysate flow rate (Qd) is adjusted to 30% of Qb to ensure optimal saturation

OTHER

Standard of Care (Non-CRRT Management)

Patients with Stage 2-3 AKI who do not meet the criteria for CRRT or are managed with conservative medical therapy according to the attending clinician's decision. These patients receive routine ICU care without extracorporeal treatment.

Sponsors & Collaborators

  • Gulhane Training and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-03-15
Completion
2025-12-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07467889 on ClinicalTrials.gov